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DObjective: The study objective was to determine the predictors of postoperative atrial fibrillation (POAF) in pa-
tients randomized to conventional coronary artery bypass graft (on-pump coronary artery bypass [ONCAB])
versus beating heart coronary surgery (off-pump coronary artery bypass [OPCAB]).
Methods: The subgroup of 2103 patients (of 2203 enrollees) in the Randomized On Versus Off Bypass trial with
no POAF was studied (1056 patients in the ONCAB group and 1047 patients in the OPCAB group). Univariate
and multivariate analyses were used to identify the predictors of POAF and the impact of POAF on outcomes.
Results:Use of ONCAB versus OPCABwas not associated with increased rates of POAF. Older age (P<.0001),
white race (P<.001), and hypertension (P<.002) were predictors of POAF on multivariate analysis. In general,
POAF led to a higher rates of reintubation (ONCAB: 6.3% vs 0.8% no POAF, P<.001; OPCAB: 7.4% vs 1.8%
no POAF, P<.0001) and prolonged ventilatory support (ONCAB: 7.1% vs 2.3% no POAF, P¼ .001; OPCAB:
9.2% vs 3.4% no POAF,P¼ .0003). The rate of any early adverse outcomewas higher in patients with POAF (all
patients: 10% POAF vs 4.7% no POAF, P<.0001; ONCAB: 9% POAF vs 4.3% no POAF, P¼ .008; OPCAB:
11% POAF vs 5.1% no POAF, P¼ .001). The 1-year all cause mortality was higher with POAF for both groups
(ONCAB: 5.4% POAF vs 2% no POAF,P¼ .009; OPCAB: 5.1% POAF vs 2.6% no POAF,P¼ .07). POAFwas
independently associated with early composite end point (odds ratio [OR], 2.23; confidence interval [CI],
1.55–3.22; P<.0001), need for new mechanical support (OR, 3.25; CI, 1.39–7.61; P ¼ .007), prolonged venti-
latory support (OR, 2.93; CI, 1.89–4.55; P<.0001), renal failure (OR, 5.42; CI, 1.94–15.15; P ¼ .001), and
mortality at 12 months (OR, 1.94; CI, 1.14–3.28; P ¼ .01).
Conclusions: In the Randomized On Versus Off Bypass trial, the strategy of revascularization did not affect the
rate of POAF. Age, race, and hypertension were predictors of POAF. POAF was independently associated with
a higher short-term morbidity and higher 1-year mortality rates. (J Thorac Cardiovasc Surg 2012;143:93-102)Earn CME credits at
http://cme.ctsnetjournals.org
Postoperative atrial fibrillation (POAF) remains the most
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The Journal of Thoracic and Climiting, POAF can adversely affect patients’ outcomes in
terms of morbidity, mortality, intensive care unit and hospi-
tal stay, and long-term outcome.1-4 In a prior publication,
we had outlined the predictors of POAF and the
relationship of POAF to postoperative events in a large
observational Veterans Affairs (VA) cooperative study.1
At the time of that study, beating heart CABG (off-pump
coronary artery bypass [OPCAB]) was not yet practiced
by surgeons in the United States. Although there are multi-
ple reports on the predictors of POAF in patients undergo-
ing conventional CABG with the use of cardiopulmonary
bypass (on-pump coronary artery bypass [ONCAB]),1-4
data are lacking in a large multi-institution group of patients
undergoing OPCAB. Available data are from single center
studies with a small patient sample size.5,6 The aim of
this study was to identify the predictors of POAF for
patients undergoing CABG procedures and to elucidate
the impact of POAF on patients’ outcome comparing
OPCAB with ONCAB strategies.RANDOMIZED ON VERSUS OFF BYPASS TRIAL
The Randomized On Versus Off Bypass (ROOBY) trial
was a prospective, randomized, single blinded, multicenter,ardiovascular Surgery c Volume 143, Number 1 93
Abbreviations and Acronyms
AF ¼ atrial fibrillation
CABG ¼ coronary artery bypass grafting
CI ¼ confidence interval
FFP ¼ fresh-frozen plasma
ONCAB ¼ on-pump coronary artery bypass
OPCAB ¼ off-pump coronary artery bypass
OR ¼ odds ratio
POAF ¼ postoperative atrial fibrillation
RBC ¼ red blood cell
ROOBY ¼ Randomized On Versus Off Bypass
VA ¼ Veterans Affairs
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DVA cooperative study conducted at 18 VA medical centers
between February 2002 and May of 2008, enrolling 2203
patients. Data were prospectively collected by a dedicated
research nurse at each participating institution. The
ROOBY trial’s primary short-term end point was a compos-
ite of death or complications (reoperation, new mechanical
support, cardiac arrest, stroke, and renal failure) before hos-
pital discharge or within 30 days. For 1-year follow-up, the
primary ROOBY trial’s longer term end point was a com-
posite of all-cause death and repeat revascularization or
nonfatal myocardial infarction occurring between 30 days
and discharge up to 1-year follow-up. The details of the
main ROOBY trial have been published.7 Participating in-
stitutions are outlined in Appendix 1. The current study ex-
tracted ROOBY trial patient data to examine the predictors
of POAF in the off-pump versus on-pump patient cohorts
and the effect of atrial fibrillation (AF) on outcomes in pa-
tients overall and in both groups.
The ROOBY trial protocol, including the present
subanalysis, was approved by each participating VA Medi-
cal Center’s Institutional Review Board and Research and
Development Office. Informed consent was obtained for
each patient, and a Health Insurance Portability and Ac-
countability Act waiver of authorization was provided.MATERIALS AND METHODS
AF was defined as any abnormal atrially originated irregular rhythm
lasting more than 30 minutes. Because this ROOBY trial subanalysis
was focused to identify the predictors related to patients with new AF as
a new postoperative complication, all patients with preoperative AF were
excluded. Thus, a total of 2103 ROOBY trial patient records (95.5% of
ROOBY trial enrollees, n ¼ 2203) were extracted for this ROOBY trial
subanalysis. As part of the original ROOBY trial, preoperative demograph-
ics, intraoperative practice parameters, and postoperative outcome data
were collected. On the basis of each local center’s standard of care, both
off-pump and on-pump groups received comparable postoperative care,
such as monitoring in the intensive care unit or telemetry ward until dis-
charge from the hospital.
All ROOBY trial patients were closely followed by the research nurse
every 2 months by phone until 1 year post-CABG when they were94 The Journal of Thoracic and Cardiovascular Surgerequested to return for follow-up coronary angiogram and neuropsycho-
logic testing. Of the 2103 patients included in this subanalysis, 1636
(77.79%) returned for 1-year follow-up with a similar percentage be-
tween groups.
Statistical Methods
More than 100 variables (deemed clinically relevant to a patient’s pre-
disposition for POAF including preoperative clinical and laboratory param-
eters (Appendix 2) and off-pump versus on-pump strategy were compared
using univariate analyses for patients with and without POAF complica-
tions. As appropriate to the ONCAB versus OPCAB treatment received,
the intraoperative surgical variables and postoperative care variables data
were assessed for a possible univariate association with POAF.
The 2 groups (with and without POAF) being used in this subanalysis
means that only larger differences will be significant and that there is re-
duced power. Because this is a subanalysis with 2 comparison groups
and multiple outcome measures, a P value of .01 is considered significant.
For univariate analyses, chi-square or Fisher exact tests were used to
compare the patient subgroups for the discrete variables, and t tests or anal-
ysis of variance techniques were used for continuous variables. Log-rank
tests with Kaplan–Meier curves were used to report time until death. Mul-
tivariable logistic regression analyses were used to identify predictors of
POAF and to determine the significance of POAF on the 30-day and
1-year composite measures, holding other baseline patient characteristics
constant. In separate analyses and in addition to on-pump versus off-
pump treatment effect, variables with significant association with POAF
on univariate analysis at P¼ .05 were entered into multivariate logistic re-
gression model. Propensity matching techniques were used to corroborate
the results of the multiple logistic regression findings.RESULTS
Demographics and medical characteristics were similar
in both groups at randomization. The incidence of POAF
in the entire series was 26.2% (551 patients) ranging
from 12.14% to 35.29% among the 18 participating cen-
ters. Patients in the POAF group were older than patients
in the no POAF group (mean age, 65.3  8.5 years vs
61.6  8.2 years; P<.0001). POAF developed in 268 of
1056 patients (25.4%) in the ONCAB group and in 283
of 1047 patients (27%) in the OPCAB cohort (P ¼ .40).
Thus, there was no difference in POAF rates based on ON-
CAB versus OPCAB strategy of revascularization.
There was no difference between ONCAB and OPCAB
groups regarding the postoperative day that AF occurred
or the conversion back to a sinus rhythm (2.8  2.3 days
vs 2.7  2.5 days, respectively, for POAF occurrence,
P ¼ .84, and 4.1  2.9 days vs 4.0  3.0 days for conver-
sion, P ¼ .57). Likewise, the use of prophylactic antiar-
rhythmic medications did not affect the incidence of
POAF in either group. A total of 508 patients (92.2%)
with POAF received medications for treatment of AF.
Moreover, 95.3% of patients (range, 82.6%–100%) con-
verted back to a sinus rhythm. Electrical cardioversion
was required in 10.2% of patients (range, 0.0%–22.6%).
Across both revascularization strategies, there were sev-
eral differences in the rates of complications observed be-
tween POAF and no POAF groups. Prolonged ventilatory
support for more than 48 hours was required in 45 of 551ry c January 2012
TABLE 1. Preoperative demographics of patients with and without postoperative atrial fibrillation
All patients ONCAB OPCAB
POAF
(551)
No POAF
(1552) P value
POAF
(268)
No POAF
(788) P value
POAF
(283)
No POAF
(764) P value
Age (y) 65.3  8.5 61.6  8.2 <.0001 65.4  8.5 61.3  8.3 <.0001 65.1  8.5 62  8.2 <.0001
HTN 494 (90%) 1218 (85%) .005 242 (90%) 671 (85%) .04 252 (89%) 647 (85%) .07
COPD 130 (24%) 297 (19%) .03 70 (26%) 153 (19%) .02 60 (21%) 144 (19%) .43
Diabetes 254 (46%) 664 (43%) .19 128 (48%) 342 (43%) .23 126 (44.5%) 322 (42%) .53
Serum creatinine>1.5 59 (11%) 106 (7%) .006 27 (10%) 48 (6%) .04 32 (11%) 58 (8%) .06
PVD 105 (19%) 218 (14%) .006 47 (17.5%) 109 (14%) .16 58 (20.5%) 109 (14%) .02
EF<45% 80 (14.5%) 263 (17%) .20 44 (16%) 135 (17%) .85 36 (13%) 128 (17%) .13
Current smoker 154 (28%) 561 (36%) .001 78 (29%) 294 (37%) .02 76 (27%) 267 (35%) .04
ONCAB, On-pump coronary artery bypass; OPCAB, off-pump coronary artery bypass; POAF, postoperative atrial fibrillation; EF, ejection fraction; COPD, chronic obstructive
pulmonary disease; HTN, hypertension; PVD, peripheral vascular disease.
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Dpatients (8.2%) with POAF compared with 44 of 1551
patients (2.8%) with no POAF (P<.0001) . For the entire
series, age, hypertension, renal dysfunction with a serum
creatinine greater than 1.5, and peripheral vascular disease
were all associated with POAF on univariate analysis
(Table 1). Table 1 also shows comparison of ONCAB and
OPCAB groups.
By using nonparametric test (Wilcoxon test) for the com-
parison of POAF versus no POAF for units of red blood cells
(RBCs) and fresh-frozen plasma (FFP) transfused and vol-
ume of salvaged blood reinfused, the parameters associated
with POAF in the entire series included more use of packed
RBCs, FFP, and higher volume of salvaged blood reinfused:
RBC 1.2  2 units POAF, 0.9  1.7 units no POAF,
P ¼ .0009; FFP 0.6  1.5 units POAF, 0.4  1.3 units no
POAF, P ¼ .001; salvaged blood 582  513 mL POAF,
504  464 mL no POAF, P ¼ .001. For the OPCAB group,
the corresponding values were RBC 1.3  2.1 units POAF,
0.9  1.6 units no POAF, P ¼ .001; FFP 0.7  1.7 units
POAF, 0.4  1.1 units no POAF, P ¼ .003; salvaged blood
607  529 mL POAF, 513  481 mL no POAF, P ¼ .001.
For the OPCAB group, a higher volume of salvaged blood
reinfusion was associated with a higher rate of conversion
(P < .0001), take-down and redo of distal anastomoses
(P¼ .0003), and excessive bleeding (P¼ .006). In contrast,
no association was found between transfusion and POAF inTABLE 2. Thirty-day postoperative outcomes
Variables
ONCAB
POAF (%) 268 No POAF (%) 788
Operative mortality 6 (2) 6 (0.8)
Reoperation for bleeding 6 (2) 17 (2)
New mechanical support 4 (1.5) 4 (0.5)
Any reoperation 9 (3) 21 (3)
Reintubation 17 (6) 14 (2)
Prolonged ventilatory support 19 (7) 18 (2)
Renal failure 5 (2) 3 (0.4)
Any early outcome 24 (9) 34 (4)
ONCAB, On-pump coronary artery bypass; OPCAB, off-pump coronary artery bypass; PO
The Journal of Thoracic and Cthe ONCAB group (P>.02). Cardiopulmonary bypass time,
aortic crossclamp time, use of cardioplegia and mode of de-
livery, composition of cardioplegia solution, and topical ice
slush or cold saline irrigation were not associated with
a higher incidence of POAF in the ONCAB group.
In the postoperative period in both the ONCAB and OP-
CAB groups, there was a higher rate of prolonged ventila-
tory support, reintubation, and any early adverse outcome
with POAF (Table 2). There were 20 strokes in this series
of 2103 patients for an incidence of 1.0%. Of these, 9 pa-
tients (1.6%) in the POAF group had a stroke versus 11 pa-
tients (0.7%) in the no POAF group (P¼ .07). Patients with
POAF had a longer hospital stay (13.2 vs 10.3 days,
P<.0001).
The 1-year all cause mortality rate for POAF was 5.2%
vs 2.3% in the no POAF group (P<. 001). In the ONCAB
group, the 1-year mortality was 5.4% for the POAF group
versus 2% for the no POAF group (P ¼ .009). This differ-
ence was not statistically significant for the OPCAB group,
in which the mortality was 5.1% in the POAF group vs
2.6% in no POAF group (P ¼ .07). Kaplan–Meier survival
curves at 1 year for the entire series and each subgroup of
ONACB and OPCAB are depicted in Figure 1.
For all patients, logistic regression analysis revealed
older age (P<.0001), white race (P<.0006), and hyperten-
sion (P<.002) as predictors of POAF. RevascularizationOPCAB
P value POAF (%) 283 No POAF (%) 764 P value
.09 6 (2) 6 (0.80) .10
1.00 16 (6) 14 (2) .003
.12 8 (3) 7 (0.09) .04
.53 16 (6) 18 (2) .01
.001 21 (7.4) 14 (2) <.0001
.001 26 (9) 26 (3) <.0003
.03 6 (2) 3 (0.40) .01
.008 31 (11) 39 (5) .001
AF, postoperative atrial fibrillation.
ardiovascular Surgery c Volume 143, Number 1 95
FIGURE 1. One-year survival of patients with and without POAF (green represents 95% CI for POAF; yellow represents 95% CI for no POAF). A, All
patients. B, ONCAB group. C, OPCAB group. Afib, Atrial fibrillation.
Acquired Cardiovascular Disease Almassi et al
A
C
Dstrategy was not a predictor of POAF. Older age (P<.001)
was the only predictor in the OPCAB group (Table 3). In ad-
dition to the off-pump versus on-pump treatment effect and
on the basis of univariate screening, all variables identified
with an association with the presence/absence of AF at
P<.05 were deemed eligible for entry into a multivariable
logistic model. The logistic regression model’s predictive
power, as measured by the c-index, was estimated at
0.664. Older age, white race, and hypertension were theTABLE 3. Predictors of postoperative atrial fibrillation
Variable
All patients
OR 99% CI P value OR
Age 1.044 1.03–1.058 <.0001 1.
White race 1.831 1.30–2.58 <.001 2.2
Hypertension 1.760 1.23–2.50 <.002 1.9
ONCAB, On-pump coronary artery bypass; OPCAB, off-pump coronary artery bypass; OR
96 The Journal of Thoracic and Cardiovascular Surgeonly predictors of POAF on this propensity model
approach.
In separate regression analyses of early and late outcomes
using the treatment group and POAF as independent vari-
ables in addition to age, race, and hypertension, POAF
was independently associated with early composite end
point (odds ratio [OR], 2.23; confidence interval [CI],
1.55–3.22; P< .0001), need for new mechanical support
(OR, 3.25; CI, 1.39–7.61; P ¼ .007), prolonged ventilatoryONCAB OPCAB
99% CI P value OR 99% CI P value
1.03–1.07 <.0001 1. 1.01–1.053 <.0009
1.31–3.78 .003 1.5 0.94–2.39 .08
1.14–3.22 .01 1.6 1.–2.66 .05
, odds ratio; CI, confidence interval.
ry c January 2012
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Dsupport (OR, 2.93; CI, 1.89–4.55; P<.0001), renal failure
(OR, 5.42; CI, 1.94–15.15; P ¼ .001), and mortality at 12
months (OR, 1.94; CI, 1.14–3.28; P ¼ .01). Treatment
group was not a factor.
DISCUSSION
AF continues to be a common problem after coronary ar-
tery bypass surgery. A lower incidence of POAF has been
quoted as one of the advantages of beating heart surgery
by the advocates of OPCAB technique.5,8 The literature
contains conflicting reports regarding POAF in patients
undergoing OPCAB versus ONCAB.9,10 The present
report is the largest randomized comparison of patients
undergoing ONCAB and OPCAB in whom the data for
the POAF and its management were prospectively
collected from the early stages in the study. In addition,
patients’ characteristics were similar at randomization.
The treatment group did not have an impact on the
incidence of POAF. In a recent report of long-term fol-
low-up of patients in the MASS III trial, the incidence of
POAF in those undergoing OPCAB was 35% versus 4%
for those undergoing ONCAB.11 The low incidence of
POAF in the ONCAB group in the MASS III trial was at-
tributed to the routine administration of corticosteroids to
patients undergoing ONCAB, although the methods of post-
operative monitoring were not detailed in this study.
In almost all reported series, older age has been a risk fac-
tor for the development of POAF.1,2,4,6 Development of
fibrosis in the atria and structural changes in the heart
associated with aging may be some of the contributing
factors for a higher incidence of POAF in older
patients.12,13 In the current series and for both groups,
older age was a predictor of POAF.
White race was associated with a significantly higher in-
cidence of POAF. The association of race and POAF has not
been well reported in the literature. Most studies are from
population survey or epidemiologic studies. In the Large
Health Survey of Veteran Enrollees in 664,754 male re-
sponders, the age-adjusted prevalence of AF was 5.7% in
whites versus 3.4% in blacks and 3% in Hispanics.14 An-
other study using pooled data from 3 cohort studies with ad-
justment for potential confounders found 3.8-fold greater
odds for whites having AF than African Americans.15
White race was associated with a higher rate of POAF in
a recent large retrospective study.4
The use of cardiopulmonary bypass, right atrial cannula-
tion, and the systemic inflammatory response have all been
cited as reasons for a purportedly higher incidence of POAF
in patients undergoing ONCAB.5,16 Our report is the first
large-scale, prospectively randomized study to show that pa-
tients undergoing coronary revascularization with the OP-
CAB technique did not have a lower incidence of POAF
than patients undergoing ONCAB. In support of this finding
is the fact that cardiopulmonary bypass was not found to beThe Journal of Thoracic and Cassociated with POAF on univariate or multivariable analy-
sis. Moreover, the method of myocardial protection in ON-
CAB group had no impact on the incidence of POAF. This
implies that the mechanism of POAF is not related to the
cannulation of the atrium per se or the cardiopulmonary by-
pass. In fact, the ONCAB group received more grafts and
had a longer operative time, yet the AF rate was slightly
lower than in the OPCAB group. Possible left atrial stretch-
ing with heart dislocation during coronary revascularization
has been suggested as one theoretic mechanism for a higher
rate of POAF in patients undergoing OPCAB.11
The association of postoperative blood transfusion and
POAF has been reported in the literature.17 Reinfusion of
a higher volume of salvaged blood for patients undergoing
OPCAB was associated with a higher rate of POAF. This
may be related to technical difficulties in the operating
room and excessive bleeding encountered. POAF has
been associated with a higher incidence of stroke in cardiac
surgical patients.4,18,19 Overall, the stroke rate was low in
this series (20 patients, 1%). Although not statistically
significant, the stroke rate in patients with POAF
appeared to be trending higher compared with patients
with no AF (1.6% vs 0.7%, P ¼ .07). However, no
definitive statements related to these treatment arm
comparisons could be made because of low numbers of
perioperative stroke in both treatment groups.
Patients with POAF had a longer hospital stay. This is
consistent with other reports in the literature.2,4 POAF
was associated with a higher rate of in-hospital mortality
(5.8% vs 2.2%, P ¼ .003). The mortality rate at 1 year
was higher in those with POAF in both the ONCAB and
the OPCAB groups, although the P value for the OPCAB
group did not reach statistical significance. An increased
rate for 6-month mortality with POAF was first reported
by our coauthor team in an earlier publication.1 Subsequent
reports have confirmed that POAF is a predictor of late mor-
tality in patients undergoing CABG.20 The reasons behind
this increased mortality are not well understood, but older
age may be one factor (Table 1).
In conclusion, in this large prospective randomized
ROOBY trial’s substudy, an OPCAB versus ONCAB tech-
nique had no impact on the incidence of POAF. Older age,
white race, and hypertension were predictors of POAF.
Regardless of the revascularization strategy, POAF was
associated with a higher early adverse outcome and a lower
1-year survival. Given the limited successes to-datewith ex-
isting treatment approaches, it is imperative to develop and
evaluate new strategies to prevent the occurrence of postop-
erative AF that may lead to improved short-term outcome
and long-term survival in patients undergoing CABG.
Limitations
As with any VA-based study, the almost all male popula-
tion enrolled was typical of the veterans who receivedardiovascular Surgery c Volume 143, Number 1 97
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DCABG procedures during the study time frame. Therefore,
no conclusions can be drawn for female patients. However,
this study reflects the typical cardiac surgical practice for
most VA-based surgeons across different VA medical cen-
ters, given the diversity of POAF-related practice patterns
reported. Because such no statements can be made regard-
ing the wide range of POAF seen among the participating
centers, these findings are in contradistinction to other pub-
lished smaller series reported by a single surgeon or a single
institution, where the single-center’s data may not be
broadly generalizable to a community practice setting.References
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Dr David McGiffin (Birmingham, Ala). The investigators in
the ROOBY trial and the authors of this substudy are to be congrat-
ulated for taking on this important project, the results of which will
be of benefit to all of us.
At first glance, this study would seem to be straightforward.
However, in reality, it does have a number of methodological
and analytic conundrums, and I would like you to respond to a cou-
ple of concerns that I have, and we will deal with them one at
a time.
My first concern is about the relationship between postoperative
AF and the early postoperative outcome events that you examined,
including reintubation and renal failure. The use of the phrase
‘‘impact of postoperative atrial fibrillation on outcomes,’’ which
appears in the abstract, and the word ‘‘impact,’’ which appears
in your title, implies cause and effect. However, as far as I can
see from the presentation, it is possible that the outcome event
may have occurred before the episode of postoperative AF, and
furthermore, postoperative AF is frequently part of the clinical pre-
sentation of a number of outcome events, including respiratory
failure. Are you implying cause and effect, and if so, could you
reconcile the inference of cause and effect with the realities of
the study?
Dr Almassi. In regard to the cause and effect, it is really diffi-
cult, like the chicken and egg question, which one came first, but in
terms of the incidence of AF, we have the occurrences, as I showed
here, when it occurred. But in terms of the AF, I don’t have the data
to show when, for example, renal failure developed. However, the
reintubation and mechanical support, prolonged mechanical sup-
port beyond 48 hours, would indicate that AF probably happened
earlier, but I don’t have the data to show that that is in fact the case.
Because the patients were similar in baseline characteristics at ran-
domization, it would seem that postoperative AF may be the cause
rather than the effect, although, as I said, with the data as they are, I
cannot state with certainty that is the case.
Dr McGiffin. So my summary of that would be that before
claiming cause and effect or impact, this would require consider-
ably more analysis?
Dr Almassi. We can certainly see association. I agree with you.
DrMcGiffin.Another concern is the suggestion from your pre-
sentation that the occurrence of postoperative AF is a determinant
of survival 12 months after operation, which is implied from your
Kaplan–Meier curves of survival, stratified by the presence or ab-
sence of postoperative AF. I think one could fairly ask the question,
what does 30 minutes of postoperative AF have to do with in-
creased probability of dying over the next 12 months? An alterna-
tive explanation is that postoperative AF is really amarker for an as
yet unidentified cause of death. I think that before concluding that
the occurrence of postoperative AF directly and adversely affects
survival 12 months after surgery, a thorough investigation of the
late causes of death and their relationship to postoperative AF
would need to be undertaken. If you are hypothesizing a cause-
and-effect relationship between postoperative AF and latery c January 2012
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that would lead you to this inference?
Dr Almassi.We do not have the causes of late death. However,
we did a number of multivariate analyses in terms of the different
effects, such as the cardiopulmonary bypass circuit and the inter-
action between the technique of surgery versus other factors, and
in all of these, AF stood out as the significant factor rather than
other causes. However, because we do not have the exact cause
of death in the patients who died, I could not give an answer in
terms of why they died.
However, the available information in the literature, which is
mainly from retrospective analysis and some data from Italy on au-
topsy of patients who died postoperatively in AF, indicates that
most of the deaths in those retrospective studies were cardiac.
DrMcGiffin. So perhaps it would be fair to say that we need to
temper the inference that there is a cause-and-effect relationship
between early postoperative AF and late mortality at this stage?
Dr Almassi. Yes.
Dr McGiffin. Finally, I think you have put to rest the idea that
postoperative AF is caused by purely atrial cannulation for cardio-
pulmonary bypass and the consequences of myocardial protection
in the ONCAB group. One possible mechanism of postoperative
AF that is common to both the ONCAB and OPCAB techniques
is pericardial inflammation. Now, this would seem to have support
from animal models in which AF can be readily induced by peri-
cardial inflammation and the known efficacy of corticosteroids in
preventing postoperative AF.
In light of your findings, what are your thoughts on the mecha-
nism of postoperative AF and are there perioperative measures that
you would recommend to reduce the incidence of postoperative
AF?
Dr Almassi.We do not know the exact mechanism of postoper-
ative AF. There are no available studies that have shown that.
Therefore, any strategies that have been used—and there is plenty
of information in the literature on various strategies, atrial pacing,
as we yesterday heard about biatrial pacing, different medications
that are used, method of use of medication, length of preoperative
use, and intra- and postoperative use—everything has been tried,
and none have proven successful in preventing postoperative AF.
In our analysis we have looked at the perioperative use of antiar-
rhythmic medications, and that did not seem to have an impact
on the postoperative AF incidence. As you mentioned, cardiopul-
monary bypass and the method of myocardial preservation in the
ONCAB group did not have any effect on the rate of AF. So I
am not sure that I have any strategy to prevent postoperative AF
at this time.
Dr Niv Ad (Falls Church, Va). I have 2 issues that I believe
would require clarifications. The definition of AF as an event of
30 minutes or longer is unique. Can you tell us how did you decide
to define it in such a way? It is hard to believe that a short event
would have an impact and 30 minutes can’t be compared with 1
hour and longer.
The second comment I have is related to your conclusions with
regard to the future treatment of POAF. It seams to me that the dataThe Journal of Thoracic and Cshould be analyzed further because some of centers had only an ap-
proximately 10% rate of postoperative AF, whereas the others had
more than 30%. This leads to a potential bias in which not all cen-
ters treated their patients the same and the management of perio-
perative antiarrhythmic drugs across all centers was different?
Dr Almassi. No, it was not. Every center for the 2 groups in the
study used their standard of care at each center. That doesn’t mean
that all centers used the same protocol, no.
In terms of the incidence of AF, as I showed among centers here,
it was from 12.14% to 35%. Some of the reported incidences de-
pend on the method of monitoring patients and the extent of mon-
itoring. If a patient is only monitored in the intensive care unit and
then on the stepdown or telemetry unit, there is no monitoring, just
relied on physical examination and an occasional electrocardio-
gram, clearly the incidence of postoperative AF is going to be
underestimated. To enter into the study in terms of following pa-
tients with AF, we used a minimum of 30 minutes being in AF.
That doesn’t mean that patients converted to sinus rhythm imme-
diately. We didn’t want to include any patients who developed AF
for 1 or 2 minutes to be included in this study. Therefore, we used
that definition, more than 30 minutes.
Dr Ad. Okay, thank you, but I believe that you should include
those 2 points in your study limitations.
Dr Almassi. Okay.
Dr Richard Shemin (Los Angeles, Calif). I want to echo the
concerns that Dr Ad brought up, the variation in preoperative pro-
phylaxis and the variation in the study from 10% to 30%. Again, I
am concerned about the definition. We are measuring a postopera-
tive outcome of AF, and I am still not sure what 30 minutes of AF
means. If someone goes into AF in the intensive care unit or on the
floor and they get amiodarone and they convert within 10 minutes,
does that mean they did not have AF?
Dr Almassi. For the study, that doesn’t mean they didn’t have
AF. Yes, they did. But to include them in this study for the sake
of follow-up, we picked 30 minutes. You can pick a minute or
any episode of AF. For this study, for the numbers that we have,
which is large enough, those patients who had AF were similar
at baseline and after randomization, but the outcome was not as
good as the patients with no postoperative AF. That is the message
that our data show.
Dr Frank Baciewicz (Detroit, Mich). The Society of Thoracic
Surgery in Michigan looks at all the differences between hospitals,
and one of the things they look at is AF, which has been looked at
carefully. We have not been able to glean out any differences in
why one hospital has a 10% and one has a 30% rate of AF. Have
you been able to glean that out? I knowyoumentioned that themon-
itoring certainly makes a difference, and our data were looked at
carefully and we can’t seem to find anything. Could you find any
difference between the hospitals to explain this variation?
Dr Almassi. I don’t have those data, no. But when we looked at
each individual hospital, there was no difference in AF between
the patients who underwent OPCAB versus the on-pump group.
That we know. But in terms of the practice for each individual hos-
pital, I don’t have those data, no.ardiovascular Surgery c Volume 143, Number 1 99
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ROOBY trial participating medical centers Principle investigator Study coordinator
VA Medical Center, Albuquerque, NM Stuart Pett, MD Jeannie Coltz, RN
VA Medical Center, Asheville, ND John Lucke, MD Mariette Coyle, RN
VA Medical Center, Cleveland, Ohio Diana Whittlesey, MD Barbara Bauer, RN
VA Medical Center, Dallas, Tex Michael Jessen, MD Wanda Frey, RN
VA Medical Center, Denver, Colo Joseph Cleveland, MD Shauna Brennan, RN
VA Medical Center, Durham, NC Shu Lin, MD Jean Kistler, RN
VA Medical Center, Gainesville, Fla Edward Staples, MD Jan Hutchinson, RN
VA Medical Center, Los Angeles, Calif Abbas Ardehali, MD Eileen Ziff, RN
VA Medical Center, Manhattan, NY Eugene Grossi, MD Estelita Antoeola, RN
VA Medical Center, Miami, Fla Kushagra Katariya MD Michele Landi, RN
VA Medical Center, Milwaukee, Wis G. Hossein Almassi, MD Sharon Pecsi, RN
VA Medical Center, Palo Alto, Calif Thomas Burden, MD Gerald Georgette, RN
VA Medical Center, Pittsburg, Pa Marco Zenati, MD Jennifer Gabany, RN
VA Medical Center, Portland, Ore Passala Ravichandran, MD Karina Dana, RN
VA Medical Center, San Antonio, Tex Edward Sako, MD Regina Whitener, RN
VA Medical Center, Tampa, Fla Dimitri Novitzky, MD Jennifer Shippy, RN
VA Medical Center, Washington, DC Pendleton Alexander, MD Mary Bloom, RN
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APPENDIX 2. Variables used for analyses
Variable Measurement
Baseline/preoperative variables
1. Age y
2. Race
3. No. of previous cardiac surgeries
requiring CPB
No.
4. No. of previous cardiac surgeries not
requiring CPB
No.
5. No. of previous cardiac surgical
procedures
No.
6. Ejection fraction
7. Elective surgery Yes – No
8. Valve disease Yes – No
9. Mitral valve regurgitation Yes – No
10. Mitral valve stenosis Yes – No
11. Aortic valve regurgitation Yes – No
12. Aortic valve stenosis Yes – No
13. Left ventricular aneurysm Yes – No
14. COPD Yes – No
15. Serum creatinine>1.5 mg/dL Yes – No
16. Direct bilirubin>0.5 mg/dL Yes – No
17. CVA Yes – No
18. Peripheral vascular disease Yes – No
19. Diabetes Yes – No
20. Hypertension Yes – No
21. Hyperlipidemia Yes – No
22. Other major comorbidity Yes – No
23. CPK–MB % of total;
ng/mL; or IUL
24. Total CPK U/L
25. Troponin I ng/mL
26. C–reactive protein mg/dL
27. Smoking history Never, former,
current
28. Previous revascularization by CABG Yes – No
29. Beta–blocker use Yes – No
30. ACE inhibitor use Yes – No
31. Lipid-lowering medication use Yes – No
32. Received prophylactic antiarrhythmics Yes – No
33. Timing of prophylactic
antiarrhythmics
Day of surgery,
1 d preoperatively,
>1 d preoperatively
34. Current smoker Yes – No
Intraoperative assessments
35. Lowest hematocrit during surgery %
36. Units of packed RBC used No. units
37. Units of FFP transfused No. units
38. Unites of platelets transfused No. units
39. Volume of salvaged blood transfused No. units
40. Units of cryoprecipitate No. units
41. Cell saver used Yes – No
42. Pump sucker used Yes – No
43. Amicar used intraoperatively Yes – No
44. DDAVP used intraoperatively Yes – No
45. Aprotinin used intraoperatively Yes – No
(Continued)
APPENDIX 2. Continued
Variable Measurement
46. Other antifibrinolytic agent used
intraoperatively
Yes – No
47. Lowest systemic temperature Degrees C
48. Heparin-bonded circuit used Yes – No
49. Coated system used Yes – No
50. Coating tip to tip when coating used Yes – No
51. Lowest core temperature Degrees C
52. Any intraoperative complications Yes – No
53. New mechanical support requiring
IABP
Yes – No
54. New mechanical support requiring
ventricular assist device
Yes – No
55. Excessive bleeding require>4 units
packed RBCs
Yes – No
56. Take–down and redo distal
anastomoses
Yes – No
57. Cardiac arrest or ventricular fibrillation
after arrival in operating room
Yes – No
58. Chest left open after surgery Yes – No
59. Conversion to other treatment arm Yes – No
60. Any other major complications Yes – No
61. No myocardial preservation technique
for patients on CPB
Yes – No
62. Cold antegrade cardioplegia for
patients on CPB
Yes – No
63. Warm antegrade cardioplegia for
patients on CPB
Yes – No
64. Cold retrograde cardioplegia for
patients on CPB
Yes – No
65. Warm retrograde cardioplegia for
patients on CPB
Yes – No
66. Fibrillatory arrest for patients on CPB Yes – No
67. Topical cold saline for patients on CPB Yes – No
68. Topical ice slush for patients on CPB Yes – No
69. Heart jacket for patients on CPB Yes – No
70.Myocardial temperature monitoring for
patients on CPB
Yes – No
71. Myocardial pH monitoring for patients
on CPB
Yes – No
72. Composition of cardioplegia for
patients on CPB
None, blood,
crystalloid, both
73. Total bypasses performed No.
74. CPB time min
75. Aortic crossclamp time min
Postoperative assessments
76. CPK–MB % of total;
ng/mL; or IUL
77. CPK total U/L
78. Troponin I ng/mL
79. No inotropic agent used for>24 h Yes – No
80. Dopamine used for>24 h Yes – No
81. Dobutamine used for>24 h Yes – No
82. Epinephrine used for>24 h Yes – No
83. Norepinephrine used for>24 h Yes – No
84. Amrinone used for>24 h Yes – No
(Continued)
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Variable Measurement
85. Other inotropic agent used for>24 h Yes – No
86. IABP time h
87. Ventricular assist device time h
88. Units of RBC transfused during
first 48 h
No. units
89. Units of FFP transfused during
first 48 h
No. units
90. Units of platelets transfused during
first 48 h
No. units
91. Units of cryoprecipitate during
first 48 h
No. units
92. C-reactive protein mg/dL
93. History of AF before surgery Yes – No
94. Postoperative CVA/stroke Yes – No
95. Days CVA/stroke developed
postoperatively
d
96. Patient reintubated Yes – No
97. Redo CABG Yes – No
98. Prophylactic antiarrhythmics given Yes – No
99. Amiodarone given Yes – No
100. Beta–blocker given Yes – No
101. Both amiodarone and beta–blocker
given
Yes – No
102. Other antiarrhythmic given Yes – No
103. POAF Yes – No
104. Day POAF developed
105. Prolonged ventilator support Yes – No
106. Tracheostomy Yes – No
107. Any early outcome Yes – No
108. Any late outcome Yes – No
109. Death 12 mo Yes – No
110. Myocardial infarction, 12 mo Yes – No
111. Revascularization, 12 mo Yes – No
CPB, Cardiopulmonary bypass; COPD, chronic obstructive pulmonary disease; CVA,
cerebrovascular accident; CPK-MB, creatine phosphokinase-MB; ACE, angiotensin-
converting enzyme; DDAVP, desmopressin; IABP, intraaortic balloon pump.
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